Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis

被引:0
|
作者
J. M. Hatcher-Martin
J. L. McKay
A. F. Pybus
B. Sommerfeld
J. C. Howell
F. C. Goldstein
L. Wood
W. T. Hu
S. A. Factor
机构
[1] Emory University,Jean & Paul Amos PD & Movement Disorders Program, Department of Neurology
[2] Emory University,Department of Biomedical Informatics
[3] Georgia Tech and Emory University,Wallace H. Coulter Department of Biomedical Engineering
[4] Georgia Tech,Department of Mechanical Engineering
[5] Neurology Consultants of Dallas,Neuropsychology Program, Department of Neurology
[6] Emory University,Alzheimer’s Disease Research Center, Emory University and Cognitive Neurology Division, Rutgers
[7] Health Care Policy,Robert Wood Johnson Medical School and Institute for Health
[8] and Aging Research,Department of Neurology
[9] SOC Telemed,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We explore the association between three Alzheimer’s disease-related and ten inflammation-related CSF markers and freezing of gait (FOG) in patients with Parkinson’s disease (PD). The study population includes PD patients with FOG (PD-FOG, N = 12), without FOG (PD-NoFOG, N = 19), and healthy controls (HC, N = 12). Age and PD duration are not significantly different between groups. After adjusting for covariates and multiple comparisons, the anti-inflammatory marker, fractalkine, is significantly decreased in the PD groups compared to HC (P = 0.002), and further decreased in PD-FOG compared to PD-NoFOG (P = 0.007). The Alzheimer’s disease-related protein, Aβ42, is increased in PD-FOG compared to PD-NoFOG and HC (P = 0.001). Group differences obtained in individual biomarker analyses are confirmed with multivariate discriminant partial least squares regression (P < 0.001). High levels of Aβ42 in PD-FOG patients supports an increase over time from early to advanced state. Low levels of fractalkine might suggest anti-inflammatory effect. These findings warrant replication.
引用
收藏
相关论文
共 50 条
  • [41] Cerebrospinal fluid biomarkers and cognitive impairment in patients with early Parkinson's disease
    Stav, A. L.
    Arsland, D.
    Hessen, E.
    Fladby, T.
    MOVEMENT DISORDERS, 2014, 29 : S365 - S366
  • [42] Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease
    Farotti, Lucia
    Paciotti, Silvia
    Tasegian, Anna
    Eusebi, Paolo
    Parnetti, Lucilla
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (08) : 771 - 780
  • [43] Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
    Parnetti, Lucilla
    Tiraboschi, Pietro
    Lanari, Alessia
    Peducci, Maria
    Padiglioni, Chiara
    D'Amore, Cataldo
    Pierguidi, Laura
    Tambasco, Nicola
    Rossi, Aroldo
    Calabresi, Paolo
    BIOLOGICAL PSYCHIATRY, 2008, 64 (10) : 850 - 855
  • [44] Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach
    van Dijk, Karin D.
    Teunissen, Charlotte E.
    Drukarch, Benjamin
    Jimenez, Connie R.
    Groenewegen, Henk J.
    Berendse, Henk W.
    van de Berg, Wilma D. J.
    NEUROBIOLOGY OF DISEASE, 2010, 39 (03) : 229 - 241
  • [45] The effects of gait impairment with and without disease freezing of gait in Parkinson's disease
    Josiah, Anne F.
    Gruber-Baldini, Ann L.
    Anderson, Karen E.
    Fishman, Paul S.
    Weiner, William J.
    Reich, Stephen G.
    Shulman, Lisa M.
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (03) : 239 - 242
  • [46] Author Correction: A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
    Chunchen Xiang
    Shengri Cong
    Xiaoping Tan
    Shuang Ma
    Yang Liu
    Hailong Wang
    Shuyan Cong
    npj Parkinson's Disease, 9
  • [47] Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients
    Jiguang Guo
    Zhongwu Sun
    Shifu Xiao
    Dongping Liu
    Guohua Jin
    Ersong Wang
    Jiangning Zhou
    Jiawei Zhou
    Cell Research, 2009, 19 : 1401 - 1403
  • [48] Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis
    Li, S. M.
    Zheng, Y. C.
    Yang, C.
    Wu, J. Y.
    Yu, Z. W.
    Jiang, Y.
    Feng, T.
    MOVEMENT DISORDERS, 2023, 38 : S565 - S566
  • [49] Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis
    Xie, Dan
    Feng, Ling
    Huang, Hongyan
    Zhao, Quanzhen
    Ning, Pingping
    Shen, Qiuyan
    Lu, Haitao
    Xu, Fang
    Xu, Yanming
    BEHAVIOURAL NEUROLOGY, 2021, 2021
  • [50] Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients
    Guo, Jiguang
    Sun, Zhongwu
    Xiao, Shifu
    Liu, Dong-ping
    Jin, Guohua
    Wang, Ersong
    Zhou, Jiangning
    Zhou, Jiawei
    CELL RESEARCH, 2009, 19 (12) : 1401 - 1403